Emcure Pharmaceuticals LtdQ2 FY24Pharmaceuticals & Biotechnology

Emcure Pharmaceuticals Ltd

Q2 FY24 Earnings Call Analysis

Management growth scorecard

Revenue

Category 2

Margin

Category 2

Fundraise

N/A

Order

Yes

Capex

Yes

2 of 4 growth signals are positive.

Revenue guidance

Category 2

→Emcure projects overall revenue growth of over 20% for the full year.
→India business targets growing about 200 basis points higher than the industry on an organic basis.
→The Canada market (including Mantra acquisition) expected to see robust growth in the short to medium term, with double-digit organic growth.
→International markets, including Europe and Emerging Markets, are showing positive growth trends, with Europe expecting higher sales in later quarters.
→Operational metrics such as prescription base and MR productivity are improving, with productivity expected to increase from 6.3 to around 7 by year-end.
→New manufacturing capacities and field force expansion are key growth drivers.
→R&D investment at 4%-5% aimed at product innovation and differentiated products will drive future sales.
→Planned acquisitions and in-licensing opportunities, like Sanofi, will also contribute to growth.

Category 2

→Emcure expects overall revenue growth of 20%+ for the full year FY25.
→EBITDA margin is projected between 20% to 21% for the full year, with operating leverage benefits playing out.
→Margin profile improvement of approximately 100 basis points is possible by year-end FY25 due to ramp up in new facilities and productivity gains.
→Long-term aspiration includes achieving steady-state double-digit growth in Canada market, complemented by strong international and domestic growth.
→Focus on increasing prescriptions and expanding field force to boost productivity; MR productivity expected to improve from 6.3 to about 7 by year-end.
→The company aims for a 19%-20% Return on Capital Employed (ROCE) alongside 20% growth.
→EPS accretive acquisitions are a focus, aiming to avoid dilution and support wealth creation.
→Tax provisions remain stable with no additional provisions expected for current disputes.

3 more insights locked — sign up free to unlock

→There is no mention of any current or future fundraising through debt or equity in the provided transcript.
→The company has reduced its net debt from around ₹1,550 crores prior to the IPO to close to ₹850 crores post-IPO.
→Gross debt has also decreased from about ₹2,000 crores to approximately ₹950 crores.
→Interest costs are expected to reduce going forward due to this debt reduction.
→The company focuses on organic growth, capacity expansion, and selective acquisitions but has not indicated any plans for new fundraising currently.
→If any queries remain on this topic, the company invites investors to reach out via investor relations email.

Yes

→Emcure Pharmaceuticals has a healthy order book in the Emerging Markets segment.
→Order book is strong in both non-ARV and ARV segments.
→Non-ARV segment is witnessing traction due to differentiated products.
→There is some seasonality and timing impact on Emerging Markets orders, causing quarterly volatility.
→An uptick in orders from Emerging Markets is expected going forward.
→The HIV/ARV business is expected to improve compared to the previous year after liquidation of COVID-induced stockpiling.

Yes

→Emcure has operationalized four new manufacturing facilities recently to support growth levers over the next 2-3 years in India and international markets (Page 5).
→These new capacities are expected to ramp up by year-end or early next year, potentially reducing the current 75-basis point margin drag (Page 18).
→The company continues to invest significantly in R&D, spending 4-5% annually on a differentiated product portfolio to drive future growth (Page 15).
→Emcure is actively pursuing inorganic growth opportunities including in-licensing arrangements (e.g., Sanofi cardiac portfolio) and acquisitions, with a focus on ensuring any acquisition is EPS accretive by the second year (Pages 14-15).
→Focus on expanding field force, with addition of 1,200 MRs in last 18 months, supporting distribution and market penetration (Page 5).
→The company is also working on filing and launching Semaglutide in India by March 2026 (Page 19).

How does Emcure Pharmaceuticals Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Emcure Pharmaceuticals Ltd

Rev 2Mar 2

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Emcure Pharmaceuticals Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.